top of page
Anchor 1
New About Us Light Blue X Banner Pigs DNA.jpg

About Us

About Us Page Banner V2.jpg

Did you know most regenerative medicine products come from deceased human donors?

 

When you hear “skin graft” or “tissue transplant,” you probably imagine something high-tech and futuristic. But the truth is, much of today’s regenerative medicine still relies on body parts from deceased donors. That’s right—real human tissue, harvested after death, cleaned, processed, and used to treat patients with burns, wounds, and other serious injuries.

 

Now imagine the challenges that come with that—limited supply, variable quality, and the simple fact that we’re depending on tragedy to create hope.

 

At XenoTherapeutics, we’re changing that.

 

We’ve developed realSKIN—a new kind of skin graft made not from human donors, but from genetically engineered pigs. These animals are designed specifically to provide safe, effective skin tissue that works just like human skin—potentially even better.

 

If that sounds wild, think about this: We already raise pigs by the millions for food. We’ve bred them to be safe, consistent, and high-quality—so why not also use them to save lives?

 

From pigs to patients, we’re building a new model for regenerative medicine.

 

By creating a reliable, scalable, and ethically sourced supply of transplant-ready skin, we can help millions of patients - burn victims, wound care patients, and others—with the potential to heal faster and more completely.

It’s not science fiction. It’s happening now.

 

We are XenoTherapeutics. And this is realSKIN.

2016

Foundation’s

Purpose

Pig Icon.png

Advance the

science of xenotransplantation towards

therapeutic reality.

Handshake Icon.png

Collaborate

with partners, investigators and academic institutions to develop new regenerative medicine therapies.

Heart Icon.png

Lead xenotransplantation to become the

new standard

for regenerative medicine.

Leadership Built for Translation, Regulation, and Stewardship

XenoTherapeutics is led by a multidisciplinary team spanning clinical medicine, engineering, regulatory strategy, and translational science. Together, we focus on executing defined regulatory pathways, building reliable source systems, and advancing regenerative therapies from validated science to approved clinical use.

JAdkins 2024 B&W.jpg

JON ADKINS, M.B.A.

Co-Founder,

Director and President

  • 20+ years in medical device and regenerative medicine, with leadership roles at Smith & Nephew, Zimmer Biomet, Bacterin (now Xtant Medical), and DePuy (Johnson & Johnson).

  • Co-founded XenoTherapeutics and led realSKIN, the first skin xenotransplant designated a Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug, from first-in-human studies through clinical validation.

  • Directs the Foundation’s governance, finance,  and business development, including the stewardship and partnering of realSKIN’s clinical and regulatory assets.

  • Also serves as President of Xeno Acquisition Corp, the Foundation’s wholly owned subsidiary, which acquires biotechnology companies and manages their wind-downs, asset transfers and contingent value rights, including ESSA Pharma and Repare Therapeutics.

  • Holds a B.A. from the University of Florida and an M.B.A. in Healthcare Management from Southern New Hampshire University.

Paul Holzer_edited.jpg

PAUL HOLZER, D.Eng, M.S, 

Co-Founder,

Head of Engineering

  • Leads engineering, embryology, and source-animal development supporting the clinical and regulatory advancement of realSKIN and future regenerative tissue products.

  • Designs FDA-regulated 351(a) BLA protocols and biostatistics, supporting translational systems for preclinical and clinical programs.

  • Actively clones IGA source animals and performs CRISPR, SCNT, and embryo transfer to produce consistent, high-quality donor lines.

  • Lead inventor on 20+ patents spanning xenotransplantation methods, processing, genetic edits, and AI-enabled regenerative therapies.

  • Former U.S. Navy SEAL officer, bringing operational discipline and executional rigor to complex, high-stakes programs.

  • Holds a Doctor of Engineering from Johns Hopkins University, a Master of Engineering from MIT, a Master of Science in Experimental & Molecular Medicine from Dartmouth, and an M.B.A. in Economics.

Chelsea.png

CHELSEA SUSCHENA, B.S.

Laboratory Manager

  • Life sciences leader with over 15 years of experience in biotechnology, preclinical, and clinical program management.

  • Expert in laboratory bioassay development and data analysis.

  • Expert in research team management.

  • Supports XenoTherapeutics through research, quality control, inventory management, and regulatory compliance.

  • Graduated with distinction from University of Nevada, Reno (B.S. in Biochemistry).

  • Honoree, Nevada Woman of Achievement, Nevada Women’s Fund (2023). 

Rod Monroy.jpg

ROD MONROY, Ph.D.

Chief Scientific Officer, Emeritus

  • Experienced research scientist in cell therapy R&D, GMP manufacturing, and GCP in the conduct of clinical trials. 

  • Conducted stem cell research in radiation biology and hematopoietic stem cell transplantation. (U.S.Navy)

  • Conducted investigation for the induction of tolerance in xenotransplantation at Biotransplant. 

  • Conducted phase II/III clinical trials using MSCs for the treatment of GVHD (Osiris) and hepatocytes for the treatment of Urea Cycle Disorders (Cytonet). 

  • PhD, Biochemistry, Case Western Reserve University. 

Board of Directors

Dynamic Bill copy 3.jpg

WILLIAM S. DEACON

Director

  • Senior Vice President - Wealth Management Advisor at Merrill Lynch, PIA Portfolio Manager.

  • Drives innovation on the XenoTherapeutics Board, fostering collaboration through shared expertise and a diverse background.

  • Holds degrees from The Wharton School of the University of Pennsylvania and the University of Massachusetts Amherst.

Ruta J. Laukien Website.jpg

RUTA J. LAUKIEN, J.D. MBA

Director and Treasurer

  • Strategic Advisor and Investor focused on strategic advisory in the Global Supply Chain.

  • Brings over 12 years of investment-banking experience, specializing in M&A, debt capital markets, and equity capital raises.

  • Director and Treasurer on the XenoTherapeutics Board, safeguards the mission with a focus on responsible and impactful advancements.

  • With seven years at Bear Stearns and as a former Director at C.W. Downer, Laukien contributes Wall Street prowess and deep industry knowledge, specializing in M&A and healthcare transactions.

Sam_Whiting_headshot_edited.png

SAMUEL WHITING

Director and Clerk

  • Co-Founder and Chief Strategy Officer of Lumati, a longevity and wellness platform.

  • Collaborates with WHOOP Performance Science and UCLA Sports Medicine on cold water immersion research, and is a luminary teacher at Kripalu Center for Yoga & Health.

  • Director and Clerk on the XenoTherapeutics Board, bringing a strategy and finance perspective to the Foundation’s governance and the stewardship of its mission.

  • Holds a B.S. in Business Administration in Accounting and Finance from the University of New Hampshire, with further study at Grenoble Ecole de Management in France and Harvard Business School Online.

JAdkins 2024 B&W.jpg

JON ADKINS, M.B.A.

Director and President

  • 20+ years in medical device and regenerative medicine, with leadership roles at Smith & Nephew, Zimmer Biomet, Bacterin (now Xtant Medical), and DePuy (Johnson & Johnson).

  • Co-founded XenoTherapeutics and led realSKIN, the first skin xenotransplant designated a Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug, from first-in-human studies through clinical validation.

  • Directs the Foundation’s governance, finance,  and business development, including the stewardship and partnering of realSKIN’s clinical and regulatory assets.

  • Also serves as President of Xeno Acquisition Corp, the Foundation’s wholly owned subsidiary, which acquires biotechnology companies and manages their wind-downs, asset transfers and contingent value rights, including ESSA Pharma and Repare Therapeutics.

  • Holds a B.A. from the University of Florida and an M.B.A. in Healthcare Management from Southern New Hampshire University.

After three decades of rigorous research in the field of xenotransplantation, pigs have become the preferred source for xenogeneic transplants. We believe these pigs have big potential; when unlocked, they will provide a cure for every single person.

Debbie AlexisBio Website Sig 01_11_23 V2.jpg

DEBRA McCLELLAND

Director of Operations

  • 25+ years of diverse experience in the private sector as Director and COO with experience in Project and Operations Management, overseeing 14 offices in seven states, 1,400+ personnel, and gross revenues of more than $100M.  Collaborated with the President to develop a strategic direction to ensure alignment with organizational initiatives.

  • Quality Assurance professional responsible for real-time data recording and strict compliance with Protocols, SOP's and regulatory requirements for all patient data related to clinical trials at XenoTherapeutics.

  • Assists the scientific team as a surgical assistant, providing critical support during technical procedures in the manufacturing of realSKIN®. 

  • Co-authored Minimize Risk: How to Structure Law Firm Internal Controls, a reference guide for the National Association of Legal Administrators.

New Jessica.jpg

JESSICA OLDHAM

Operations Manager

  • Over a decade of experience in operations and logistics, including roles as Chief of Staff and COO in a lobbying and media firm.

  • Fosters collaboration and communication among the Board, vendors, partners, and staff, ensuring seamless coordination and effective relationships.

  • Provides essential support for critical projects, ensuring smooth execution and adherence to timelines.

  • Assists the scientific team in data management, contributing to research and development efforts.

bottom of page